Skip to content

Localized rectal cancer

TL;DR — Rectal-cancer treatment is anatomy- and risk-dependent: high-resolution pelvic MRI, surgical-plane quality and multidisciplinary sequencing are as important as TNM. Total mesorectal excision (TME) controls the mesorectal radial route; preoperative radiotherapy reduced local recurrence but not overall survival in the Dutch TME trial at 12 years (van Gijn 2011, PMID 21596621). Total neoadjuvant therapy (TNT) moves systemic chemotherapy before surgery: RAPIDO reduced disease-related treatment failure but later showed higher locoregional recurrence, while PRODIGE 23 improved disease-free survival with neoadjuvant mFOLFIRINOX (Bahadoer 2021, PMID 33301740; Dijkstra 2023, PMID 36661037; Conroy 2021, PMID 33862000). OPRA’s response-adapted pathway achieved 5-year organ preservation in approximately half without an apparent survival penalty, with consolidation sequencing outperforming induction for preservation (Verheij 2024, PMID 37883738). Watch-and-wait is therefore an active surveillance strategy, not absence of treatment; dMMR rectal cancer is a distinct frontier after complete clinical responses to dostarlimab in a small single-arm study (Cercek 2022, PMID 35660797).

Why rectal cancer is different

The rectum lies within a confined pelvis adjacent to mesorectal fascia, sphincters, pelvic autonomic nerves and genitourinary organs. Local failure can be catastrophic; treatment can also cause permanent bowel, sexual and urinary dysfunction.

Dimension Colon Rectum
Local staging CT dominant High-resolution pelvic MRI dominant
Radial margin Mesocolic plane Circumferential resection margin/MRF central
Radiation Rare Common for locally advanced disease
Surgery Segmental colectomy TME/partial mesorectal excision; sphincter decisions
Preservation Endoscopic only for selected early lesions Watch-and-wait/local excision after response in selected patients
Functional burden Bowel change LARS, stoma, sexual/urinary effects

MRI risk map

In MERCURY, MRI predicted a clear circumferential margin with 92% specificity; 327/349 predicted-clear cases were pathologically clear (94%, 95% CI 91–96) (MERCURY Study Group 2006, PMID 16984925).

MRI feature Decision relevance
Tumor height Surgical access, sphincter and radiation field
Extramural depth Separates low-risk from deeper T3 disease
Mesorectal fascia distance Threatened radial margin and neoadjuvant need
EMVI Distant-recurrence risk
Mesorectal nodes/deposits Regional risk
Lateral pelvic nodes Region-specific treatment strategy
Sphincter/levator involvement Organ-preservation and operation feasibility

Radiologic definitions remain contested. An international survey found 16 TNM problem areas with <80% agreement, including low-rectal T stage, T4b, MRF, deposits and lateral nodes (Lambregts 2022, PMID 35254485).

TME and surgical planes

TME removes rectum and mesorectum intact along the embryologic plane. Quality of the mesorectal specimen and negative circumferential margin predict local control.

Operation Typical setting Functional/anatomic issue
Low anterior resection Sphincter-preserving resection Anastomotic leak and LARS
Abdominoperineal resection Sphincter/levator involvement or nonfunctional preservation Permanent colostomy and perineal wound
Intersphincteric resection Selected very low tumors Major bowel dysfunction risk
Local excision/TEM/TAMIS Selected early tumors or response strategy No mesorectal nodal clearance
Pelvic exenteration Selected locally advanced/recurrent disease High morbidity; specialist-center care

The Dutch TME trial showed that short-course preoperative radiotherapy added to standardized TME reduced local recurrence at 12 years but did not improve overall survival, and second-cancer/late-effect tradeoffs remained (van Gijn 2011, PMID 21596621).

Risk-adapted pathways

Not every rectal cancer needs the same neoadjuvant intensity.

Clinical state Common strategy options Evidence uncertainty
cT1 low-risk Local excision or radical resection Histologic nodal-risk accuracy
cT2N0 TME; selected preservation trials Local excision alone usually inadequate
Intermediate-risk, clear MRF TME, selective chemotherapy/radiation Overtreatment avoidance
Locally advanced/high-risk TNT followed by TME or response-adapted preservation Optimal regimen/sequence
dMMR locally advanced PD-1 blockade in specialized pathway/trials Durability and generalizability

Upper-rectal definitions vary by distance, peritoneal reflection and MRI anatomy, producing disagreement about radiation benefit (Bondeven 2016, PMID 27697137).

Long-course chemoradiation versus short-course radiation

Long-course chemoradiation delivers approximately 50 Gy with fluoropyrimidine radiosensitization and a waiting interval; short-course commonly delivers 25 Gy in five fractions. Short-course lowers visits, while long-course has a longer downstaging tradition.

STELLAR randomized short-course radiation plus chemotherapy versus long-course chemoradiation and showed noninferior 3-year disease-free survival, with differing acute-toxicity and sequencing profiles (Jin 2022, PMID 35263150).

Radiation choice depends on margin, bulk, need for regression, organ-preservation aim, access and systemic plan—not convenience alone.

Reviews of neoadjuvant radiotherapy emphasize that local-control benefit, late pelvic toxicity and evolving systemic failure must be assessed separately (Feeney 2019, PMID 31543678). Modern TNT did not invalidate this balance; it changed when chemotherapy is delivered.

Total neoadjuvant therapy

TNT completes systemic chemotherapy before surgery. Proposed advantages are earlier micrometastatic treatment, higher completion, greater response and organ-preservation opportunity; risks include toxicity, delayed surgery and local-regrowth uncertainty.

RAPIDO

RAPIDO enrolled MRI high-risk locally advanced disease. Short-course radiation followed by CAPOX/FOLFOX before TME reduced 3-year disease-related treatment failure from 30.4% to 23.7% (HR 0.75, 95% CI 0.60–0.95) versus long-course chemoradiation/TME with optional adjuvant therapy (Bahadoer 2021, PMID 33301740).

At 5 years, locoregional recurrence was higher in the experimental arm (44/431 [10%] versus 26/428 [6%]), despite the original systemic endpoint benefit (Dijkstra 2023, PMID 36661037). RAPIDO therefore embodies a real distant-versus-local-control tradeoff.

PRODIGE 23

PRODIGE 23 added six cycles of mFOLFIRINOX before chemoradiation and TME. Three-year disease-free survival was 76% versus 69% (HR 0.69, 95% CI 0.49–0.97), with higher pathologic complete response and expected triplet toxicity (Conroy 2021, PMID 33862000).

The trial population was selected and fit. mFOLFIRINOX should not be generalized to frail patients from efficacy alone.

CAO/ARO/AIO-12 and OPRA sequencing

CAO/ARO/AIO-12 compared induction versus consolidation chemotherapy around chemoradiation; consolidation improved pathologic complete response without harming long-term disease outcomes (Fokas 2022, PMID 34792531).

OPRA randomized induction versus consolidation TNT and assigned TME or watch-and-wait by response. At 5 years, disease-free survival was 71% versus 69%, and TME-free survival 39% versus 54%, favoring consolidation for preservation (Verheij 2024, PMID 37883738). The primary 2022 report established the response-adapted design (Garcia-Aguilar 2022, PMID 35483010).

Selective radiation omission: PROSPECT

PROSPECT randomized eligible intermediate-risk patients to neoadjuvant FOLFOX with selective chemoradiation for inadequate response versus routine chemoradiation. FOLFOX was noninferior for disease-free survival; only 9.1% in the FOLFOX group received preoperative chemoradiation (Schrag 2023, PMID 37272534).

Patient-reported outcomes favored FOLFOX for some acute symptoms and chemoradiation for others, with convergence over time (Basch 2023, PMID 37270691). PROSPECT applies to its eligibility population, not MRI high-risk or very low tumors seeking maximal regression.

Defining response

Response grade Endoscopy/exam MRI Typical pathway
Complete clinical response No palpable tumor; flat scar/telangiectasia, no ulcer/nodule Fibrotic low-signal bed, no suspicious nodes; DWI interpreted cautiously Watch-and-wait eligible in expert program
Near-complete Minor irregularity or equivocal imaging Small residual uncertainty Reassess after additional interval
Incomplete Definite residual tumor Residual intermediate signal/restricted diffusion or nodes TME generally recommended

Clinical complete response is not pathologic complete response. MRI predicts residual disease imperfectly, and discordant endoscopy/MRI should not be forced into a binary label (Williams 2024, PMID 39225603).

Watch-and-wait

Watch-and-wait replaces immediate TME with intensive surveillance after complete/near-complete response. Most local regrowth occurs in the first 2–3 years and is often salvageable if detected early (Yuval 2021, PMID 34389102).

Earlier syntheses framed watch-and-wait as a therapeutic strategy requiring standardized response criteria and prospective follow-up, not simply refusal of surgery (Bernier 2018, PMID 29576755). Comparative organ-preservation literature remains heterogeneous across long-course and short-course radiation backbones (Bercz 2024, PMID 39266364).

Surveillance component Purpose
Digital rectal examination Palpable mural regrowth
Endoscopy Mucosal regrowth
Pelvic MRI Wall, mesorectum and nodes
CT chest/abdomen Distant recurrence
CEA Complementary signal

OPRA secondary analysis showed organ preservation tracks graded clinical response and that near-complete responders can mature or regrow, supporting serial rather than one-time assessment (Thompson 2024, PMID 38194231).

International registry data document both salvage opportunity and the oncologic risk of delayed detection, particularly when regrowth is not promptly managed (Fernandez 2025, PMID 39467217). Watch-and-wait requires an expert surveillance system and informed acceptance of uncertainty.

dMMR rectal cancer and neoadjuvant immunotherapy

In a prospective phase II study, 12 patients with stage II/III dMMR rectal cancer completed 6 months of dostarlimab and all 12 had clinical complete response at initial reporting, with no chemoradiation or surgery during then-available follow-up (Cercek 2022, PMID 35660797).

Expanded follow-up reports high complete-response durability across dMMR rectal and other nonrectal tumors, but the evidence remains single-arm and concentrated in expert centers (Cercek 2025, PMID 40293177). Rare resistance, Lynch implications and duration of surveillance remain critical.

The result should not be extrapolated to MMR-proficient rectal cancer.

Function and late effects

TME, radiation and anastomosis can cause bowel clustering, urgency, incontinence, sexual dysfunction and urinary dysfunction. The international LARS consensus defines a broad symptom-impact syndrome rather than stool frequency alone (Keane 2020, PMID 32032141).

In a population study, 53.1% had major LARS at mean 6.7 years, which associated with worse quality of life (Pieniowski 2020, PMID 32530135). Watch-and-wait cohorts generally report better bowel function than resection, but selection and baseline response affect comparisons (Custers 2023, PMID 36988922).

Open questions

  • Which MRI/endoscopic response algorithm best minimizes occult residual disease without unnecessary TME? (Williams 2024, PMID 39225603)
  • Can RAPIDO’s distant-control benefit be retained without its locoregional-recurrence excess? (Dijkstra 2023, PMID 36661037)
  • Which patients outside OPRA-quality centers can safely enter watch-and-wait? (Verheij 2024, PMID 37883738)
  • Is PD-1 monotherapy curative for most dMMR rectal cancers, and what surveillance duration is enough? (Cercek 2025, PMID 40293177)
  • Which intermediate-risk patients can omit radiation without sacrificing preservation opportunity? (Schrag 2023, PMID 37272534)

References

  1. van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82. PMID 21596621
  2. Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42. PMID 33301740
  3. Dijkstra EA, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766-e772. PMID 36661037
  4. Conroy T, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702-715. PMID 33862000
  5. Verheij FS, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42(5):500-506. PMID 37883738
  6. Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-2376. PMID 35660797
  7. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779. PMID 16984925
  8. Lambregts DMJ, et al. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol. 2022;32(7):4991-5003. PMID 35254485
  9. Bondeven P. Cancer of the upper rectum. Dan Med J. 2016;63(10). PMID 27697137
  10. Jin J, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022;40(15):1681-1692. PMID 35263150
  11. Feeney G, et al. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol. 2019;25(33):4850-4869. PMID 31543678
  12. Fokas E, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8(1):e215445. PMID 34792531
  13. Garcia-Aguilar J, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546-2556. PMID 35483010
  14. Schrag D, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322-334. PMID 37272534
  15. Basch E, et al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023;41(21):3724-3734. PMID 37270691
  16. Williams H, et al. MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024;312(3):e232748. PMID 39225603
  17. Yuval JB, Garcia-Aguilar J. Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy. Adv Surg. 2021;55:89-107. PMID 34389102
  18. Bernier L, et al. Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. Curr Colorectal Cancer Rep. 2018;14(2):37-55. PMID 29576755
  19. Bercz A, et al. Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy. Ann Oncol. 2024;35(11):1003-1014. PMID 39266364
  20. Thompson HM, et al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2350903. PMID 38194231
  21. Fernandez LM, et al. Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer. J Clin Oncol. 2025;43(14):1663-1672. PMID 39467217
  22. Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025;392(23):2297-2308. PMID 40293177
  23. Keane C, et al. International Consensus Definition of Low Anterior Resection Syndrome. Dis Colon Rectum. 2020;63(3):274-284. PMID 32032141
  24. Pieniowski EHA, et al. Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: population-based study. BJS Open. 2020;4(5):935-942. PMID 32530135
  25. Custers PA, et al. Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach. JAMA Surg. 2023;158(5):e230146. PMID 36988922